TY - JOUR AU - Kong, Y. AU - Si, L. AU - Zhu, Y. PY - 2011 DA - 2011// TI - Large-scale analysis of KIT aberrations in Chinese patients with melanoma JO - Clin Cancer Res VL - 17 UR - https://doi.org/10.1158/1078-0432.CCR-10-2346 DO - 10.1158/1078-0432.CCR-10-2346 ID - Kong2011 ER - TY - JOUR AU - Zingg, D. AU - Debbache, J. AU - Schaefer, S. M. PY - 2015 DA - 2015// TI - The epigenetic modifier EZH2 controls melanoma growth and metastasis through silencing of distinct tumour suppressors JO - Nat Commun VL - 6 UR - https://doi.org/10.1038/ncomms7051 DO - 10.1038/ncomms7051 ID - Zingg2015 ER - TY - JOUR AU - Si, L. AU - Kong, Y. AU - Xu, X. PY - 2012 DA - 2012// TI - Prevalence of BRAF V600E mutation in Chinese melanoma patients: large scale analysis of BRAF and NRAS mutations in a 432-case cohort JO - Eur J Cancer VL - 48 UR - https://doi.org/10.1016/j.ejca.2011.06.056 DO - 10.1016/j.ejca.2011.06.056 ID - Si2012 ER - TY - JOUR AU - Young, K. AU - Minchom, A. AU - Larkin, J. PY - 2012 DA - 2012// TI - BRIM-1, -2 and -3 trials: improved survival with vemurafenib in metastatic melanoma patients with a BRAF(V600E) mutation JO - Future Oncol VL - 8 UR - https://doi.org/10.2217/fon.12.43 DO - 10.2217/fon.12.43 ID - Young2012 ER - TY - JOUR AU - Sosman, J. A. AU - Kim, K. B. AU - Schuchter, L. PY - 2012 DA - 2012// TI - Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib JO - N Engl J Med VL - 366 UR - https://doi.org/10.1056/NEJMoa1112302 DO - 10.1056/NEJMoa1112302 ID - Sosman2012 ER - TY - JOUR AU - Shaw, A. T. AU - Engelman, J. A. PY - 2013 DA - 2013// TI - ALK in lung cancer: past, present, and future JO - J Clin Oncol VL - 31 UR - https://doi.org/10.1200/JCO.2012.44.5353 DO - 10.1200/JCO.2012.44.5353 ID - Shaw2013 ER - TY - JOUR AU - Villanueva, J. AU - Vultur, A. AU - Lee, J. T. PY - 2010 DA - 2010// TI - Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by co-targeting MEK and IGF-1R/PI3K JO - Cancer Cell VL - 18 UR - https://doi.org/10.1016/j.ccr.2010.11.023 DO - 10.1016/j.ccr.2010.11.023 ID - Villanueva2010 ER - TY - JOUR AU - Nazarian, R. AU - Shi, H. AU - Wang, Q. PY - 2010 DA - 2010// TI - Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation JO - Nature VL - 468 UR - https://doi.org/10.1038/nature09626 DO - 10.1038/nature09626 ID - Nazarian2010 ER - TY - JOUR AU - Poulikakos, P. I. AU - Persaud, Y. AU - Janakiraman, M. PY - 2011 DA - 2011// TI - RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E) JO - Nature VL - 480 UR - https://doi.org/10.1038/nature10662 DO - 10.1038/nature10662 ID - Poulikakos2011 ER - TY - JOUR AU - Wagle, N. AU - Emery, C. AU - Berger, M. F. PY - 2011 DA - 2011// TI - Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling JO - J Clin Oncol VL - 29 UR - https://doi.org/10.1200/JCO.2010.33.2312 DO - 10.1200/JCO.2010.33.2312 ID - Wagle2011 ER - TY - JOUR AU - Lito, P. AU - Pratilas, C. A. AU - Joseph, E. W. PY - 2012 DA - 2012// TI - Relief of profound feedback inhibition of mitogenic signaling by RAF inhibitors attenuates their activity in BRAFV600E melanomas JO - Cancer Cell VL - 22 UR - https://doi.org/10.1016/j.ccr.2012.10.009 DO - 10.1016/j.ccr.2012.10.009 ID - Lito2012 ER - TY - JOUR AU - Liu, S. AU - Zhang, B. AU - Zhao, Y. PY - 2014 DA - 2014// TI - Association of BRAFV600E mutation with clinicopathological features of papillary thyroid carcinoma: a study on a Chinese population JO - Int J Clin Exp Pathol VL - 7 ID - Liu2014 ER - TY - JOUR AU - Robert, C. AU - Karaszewska, B. AU - Schachter, J. PY - 2015 DA - 2015// TI - Improved overall survival in melanoma with combined dabrafenib and trametinib JO - N Engl J Med VL - 372 UR - https://doi.org/10.1056/NEJMoa1412690 DO - 10.1056/NEJMoa1412690 ID - Robert2015 ER - TY - JOUR AU - Long, G. V. AU - Grob, J. J. AU - Nathan, P. PY - 2016 DA - 2016// TI - Factors predictive of response, disease progression, and overall survival after dabrafenib and trametinib combination treatment: a pooled analysis of individual patient data from randomised trials JO - Lancet Oncol VL - 17 UR - https://doi.org/10.1016/S1470-2045(16)30578-2 DO - 10.1016/S1470-2045(16)30578-2 ID - Long2016 ER - TY - JOUR AU - Khushalani, N. I. AU - Sondak, V. K. PY - 2016 DA - 2016// TI - Are we there yet? Prolonged MAPK inhibition in BRAF(V600)-mutant melanoma JO - Lancet Oncol VL - 17 UR - https://doi.org/10.1016/S1470-2045(16)30368-0 DO - 10.1016/S1470-2045(16)30368-0 ID - Khushalani2016 ER - TY - JOUR AU - Paulson, K. G. AU - Thompson, J. A. PY - 2017 DA - 2017// TI - A second chance for success with BRAF and MEK inhibitors in melanoma JO - Lancet Oncol VL - 18 UR - https://doi.org/10.1016/S1470-2045(17)30151-1 DO - 10.1016/S1470-2045(17)30151-1 ID - Paulson2017 ER - TY - JOUR AU - Barsotti, A. M. AU - Ryskin, M. AU - Zhong, W. PY - 2015 DA - 2015// TI - Epigenetic reprogramming by tumor-derived EZH2 gain-of-function mutations promotes aggressive 3D cell morphologies and enhances melanoma tumor growth JO - Oncotarget VL - 6 UR - https://doi.org/10.18632/oncotarget.2758 DO - 10.18632/oncotarget.2758 ID - Barsotti2015 ER - TY - JOUR AU - Kim, N. Y. AU - Pyo, J. S. PY - 2017 DA - 2017// TI - Clinicopathological significance and prognostic role of EZH2 expression in non-small cell lung cancer JO - Pathol Res Pract VL - 213 UR - https://doi.org/10.1016/j.prp.2017.04.002 DO - 10.1016/j.prp.2017.04.002 ID - Kim2017 ER - TY - JOUR AU - Bachmann, I. M. AU - Halvorsen, O. J. AU - Collett, K. PY - 2006 DA - 2006// TI - EZH2 expression is associated with high proliferation rate and aggressive tumor subgroups in cutaneous melanoma and cancers of the endometrium, prostate, and breast JO - J Clin Oncol VL - 24 UR - https://doi.org/10.1200/JCO.2005.01.5180 DO - 10.1200/JCO.2005.01.5180 ID - Bachmann2006 ER - TY - JOUR AU - Liu, C. AU - Liu, R. AU - Zhang, D. PY - 2017 DA - 2017// TI - MicroRNA-141 suppresses prostate cancer stem cells and metastasis by targeting a cohort of pro-metastasis genes JO - Nat Commun VL - 8 UR - https://doi.org/10.1038/ncomms14270 DO - 10.1038/ncomms14270 ID - Liu2017 ER - TY - JOUR AU - Yamaguchi, H. AU - Hung, M. C. PY - 2014 DA - 2014// TI - Regulation and role of EZH2 in cancer JO - Cancer Res Treat VL - 46 UR - https://doi.org/10.4143/crt.2014.46.3.209 DO - 10.4143/crt.2014.46.3.209 ID - Yamaguchi2014 ER - TY - JOUR AU - Mahmoud, F. AU - Shields, B. AU - Makhoul, I. PY - 2016 DA - 2016// TI - Role of EZH2 histone methyltrasferase in melanoma progression and metastasis JO - Cancer Biol Ther VL - 17 UR - https://doi.org/10.1080/15384047.2016.1167291 DO - 10.1080/15384047.2016.1167291 ID - Mahmoud2016 ER - TY - JOUR AU - Fane, M. E. AU - Chhabra, Y. AU - Hollingsworth, D. E. PY - 2017 DA - 2017// TI - NFIB mediates BRN2 driven melanoma cell migration and invasion through regulation of EZH2 and MITF JO - EBioMedicine VL - 16 UR - https://doi.org/10.1016/j.ebiom.2017.01.013 DO - 10.1016/j.ebiom.2017.01.013 ID - Fane2017 ER - TY - JOUR AU - Montagnani, V. AU - Benelli, M. AU - Apollo, A. PY - 2016 DA - 2016// TI - Thin and thick primary cutaneous melanomas reveal distinct patterns of somatic copy number alterations JO - Oncotarget VL - 7 UR - https://doi.org/10.18632/oncotarget.8758 DO - 10.18632/oncotarget.8758 ID - Montagnani2016 ER - TY - JOUR AU - Gallagher, S. J. AU - Tiffen, J. C. AU - Hersey, P. PY - 2015 DA - 2015// TI - Histone modifications, modifiers and readers in melanoma resistance to targeted and immune therapy JO - Cancers VL - 7 UR - https://doi.org/10.3390/cancers7040870 DO - 10.3390/cancers7040870 ID - Gallagher2015 ER - TY - JOUR AU - McHugh, J. B. AU - Fullen, D. R. AU - Ma, L. AU - Kleer, C. G. AU - Su, L. D. PY - 2007 DA - 2007// TI - Expression of polycomb group protein EZH2 in nevi and melanoma JO - J Cutan Pathol VL - 34 UR - https://doi.org/10.1111/j.1600-0560.2006.00678.x DO - 10.1111/j.1600-0560.2006.00678.x ID - McHugh2007 ER - TY - JOUR AU - Fan, T. AU - Jiang, S. AU - Chung, N. PY - 2011 DA - 2011// TI - EZH2-dependent suppression of a cellular senescence phenotype in melanoma cells by inhibition of p21/CDKN1A expression JO - Mol Cancer Res VL - 9 UR - https://doi.org/10.1158/1541-7786.MCR-10-0511 DO - 10.1158/1541-7786.MCR-10-0511 ID - Fan2011 ER - TY - JOUR AU - Chen, X. AU - Wang, J. AU - Shen, H. PY - 2011 DA - 2011// TI - Epigenetics, microRNAs, and carcinogenesis: functional role of microRNA-137 in uveal melanoma JO - Investig Ophthalmol Vis Sci VL - 52 UR - https://doi.org/10.1167/iovs.10-5272 DO - 10.1167/iovs.10-5272 ID - Chen2011 ER - TY - JOUR AU - Chen, H. AU - Tu, S. W. AU - Hsieh, J. T. PY - 2005 DA - 2005// TI - Down-regulation of human DAB2IP gene expression mediated by polycomb Ezh2 complex and histone deacetylase in prostate cancer JO - J Biol Chem VL - 280 UR - https://doi.org/10.1074/jbc.M501379200 DO - 10.1074/jbc.M501379200 ID - Chen2005 ER - TY - JOUR AU - Hou, P. AU - Liu, D. AU - Dong, J. AU - Xing, M. PY - 2012 DA - 2012// TI - The BRAF(V600E) causes widespread alterations in gene methylation in the genome of melanoma cells JO - Cell Cycle VL - 11 UR - https://doi.org/10.4161/cc.11.2.18707 DO - 10.4161/cc.11.2.18707 ID - Hou2012 ER - TY - JOUR AU - Li, L. AU - Zheng, H. PY - 2017 DA - 2017// TI - DNA methylation signatures and coagulation factors in the peripheral blood leucocytes of epithelial ovarian cancer JO - Carcinogenesis VL - 38 UR - https://doi.org/10.1093/carcin/bgx057 DO - 10.1093/carcin/bgx057 ID - Li2017 ER - TY - JOUR AU - Davies, M. A. AU - Saiag, P. AU - Robert, C. PY - 2017 DA - 2017// TI - Dabrafenib plus trametinib in patients with BRAFV600-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial JO - Lancet Oncol VL - 7 ID - Davies2017 ER - TY - JOUR AU - Gonzalez, M. E. AU - DuPrie, M. L. AU - Krueger, H. PY - 2011 DA - 2011// TI - Histone methyltransferase EZH2 induces Akt-dependent genomic instability and BRCA1 inhibition in breast cancer JO - Cancer Res VL - 71 UR - https://doi.org/10.1158/0008-5472.CAN-10-1933 DO - 10.1158/0008-5472.CAN-10-1933 ID - Gonzalez2011 ER - TY - JOUR AU - Obenauf, A. C. AU - Zou, Y. AU - Ji, A. L. PY - 2015 DA - 2015// TI - Therapy-induced tumour secretomes promote resistance and tumour progression JO - Nature VL - 520 UR - https://doi.org/10.1038/nature14336 DO - 10.1038/nature14336 ID - Obenauf2015 ER - TY - JOUR AU - Perico, L. AU - Mandalà, M. AU - Schieppati, A. PY - 2017 DA - 2017// TI - BRAF signaling pathway inhibition, podocyte injury, and nephrotic syndrome JO - Am J Kidney Dis VL - 70 UR - https://doi.org/10.1053/j.ajkd.2016.12.013 DO - 10.1053/j.ajkd.2016.12.013 ID - Perico2017 ER - TY - JOUR AU - Santos, M. AU - Martínez-Fernández, M. AU - Dueñas, M. PY - 2014 DA - 2014// TI - In vivo disruption of an Rb-E2F-Ezh2 signaling loop causes bladder cancer JO - Cancer Res VL - 74 UR - https://doi.org/10.1158/0008-5472.CAN-14-1218 DO - 10.1158/0008-5472.CAN-14-1218 ID - Santos2014 ER -